Fluoxetine versus phenelzine in atypical depression

Biological Psychiatry

Volumn 40, Issue 10, 1996, Pages 1017-1020

  Pande, Atul C ^a,c   Birkett, Martin ^b   Fechner Bates, Suzanne ^a   Haskett, Roger F ^a   Greden, John F ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c PFIZER INC   (United States)

Author keywords

atypical depression; drug therapy; fluoxetine; phenelzine

Indexed keywords

FLUOXETINE; PHENELZINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HEADACHE; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; TREMOR; VERTIGO;

EID: 0030588991     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-3223(95)00628-1     Document Type: Article

References (6)

1. Hamilton MA (1960): A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62.
2. Pande AC, Sayler ME (1993): Adverse events and treatment discontinuations in fluoxetine clinical trials. Int Clin Psychopharmacol 8:267-269.
3. Quitkin FM, Stewart JW, McGrath PJ, et al (1993): Columbia atypical depression: A subgroup of depressives with better response to MAOI than to tricyclic antidepressants or placebo. Br J Psychiatry 163:30-34.
4. Reimherr FW, Woods DR, Byerley W, Brainard J, Grosser BI (1984): Characteristics of responders to fluoxetine. Psychopharmacol Bull 20:70-72.
5. Stewart JW, Rabkin JG, Quitkin FM, McGrath PJ, Klein DF (1993): Atypical Depression. In Dunner DL (ed), Current Psychiatric Therapy. Philadelphia: WB Saunders Company, pp 215-220.
6. Thase ME, Mallinger AG, McKnight D, Himmelhoch JM (1992): Treatment of imipramine resistant recurrent depression: IV. A double-blind, cross-over study of tranylcypromine in anergic bipolar depression. Am J Psychiatry 149:195-198.